Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience
The paper proposes "Psychedelic‑Supportive Psychotherapy," a transtheoretical model enabling qualified psychotherapists to ethically and legally support clients before and after (but not during) psychedelic medicine experiences, combining harm reduction with facilitation of emotional, psychological and spiritual processing. It presents a foundational structure with criteria, parameters and practical recommendations that centralise the therapeutic relationship as the primary change agent and aim to expand access for diverse communities.
Authors
- Wolfson, P. E.
Published
Abstract
A renaissance is underway as research studies are substantiating psychotherapeutic and physiological benefits of psychedelic medicines, along with advancements towards legalization, expansion of professional training programs and a renewed cultural recognition of the healing qualities of the medicines. Pending legislation, a cadre of trained psychotherapists are poised to apply their expertise for those who might benefit however, they are currently largely blocked from doing so. There are also ranks of competent psychedelically informed psychotherapists who might provide support to clients engaging with the medicines but are lacking guidelines to do so.‘Psychedelic-Supportive Psychotherapy’ is a proposed model which might be immediately implemented by qualified practitioners for working with clients adjacent to but not during a medicine experience without compromising ethical or legal risk. This model aimed at psychotherapists who are increasingly challenged to help clients already engaging with or considering psychedelics, draws from the current field of knowledge to respond to a moral imperative for practitioners to act in the service of client's best interests and expand access for diverse communities. It balances psychedelic harm reduction perspectives with support for the emotional, psychological, and spiritual gains to be had when clients use psychedelics outside of therapy and can process the experience within their therapy. The model of psychedelic-supportive psychotherapy,’ is transtheoretical, its core premise being centrality of the therapeutic relationship as a change agent even as the therapist is not physically present in the client's medicine journey. Here a foundational structure is presented along with criteria, parameters, and recommendations for practitioners in its application.
Research Summary of 'Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience'
Introduction
Psychedelic medicines are increasingly recognised within psychology and broader culture as having therapeutic potential for emotional, psychological and spiritual growth, including trauma healing. Clinical trials—many led by MAPS—and expanding applications such as ketamine clinics, micro-dosing, and moves toward decriminalisation and regulated psilocybin and MDMA use have accelerated interest in integrating psychedelics into psychotherapeutic practice. At the same time, most psychedelic use remains illegal outside of approved trials, creating a gap between client demand, an informal ‘underground’ provision of guides, and a population of licensed psychotherapists who encounter clients using or considering psychedelics but lack clear, legally compliant practice guidelines. Wolfson sets out to present a practicable psychotherapeutic framework—“Psychedelic-Supportive Psychotherapy”—that licensed clinicians can adopt now to support clients who engage with psychedelic medicines outside of therapy sessions. The model emphasises harm reduction, legal and ethical prudence, and places the therapeutic relationship (the therapeutic alliance) at the centre of change, arguing that an internalised therapeutic presence can support preparation and integration even when the therapist is not present during the medicine session. The paper outlines core structure, criteria for therapist qualifications, and practical recommendations for preparation, the medicine experience, and post-medicine integration.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Topics
- APA Citation
Wolfson, E. (2023). Psychedelic-supportive psychotherapy: A psychotherapeutic model for, before and beyond the medicine experience. Journal of Psychedelic Studies, 6(3), 191-202. https://doi.org/10.1556/2054.2022.00192
References (9)
Papers cited by this study that are also in Blossom
Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)
Fadiman, J., Korb, S. · Journal of Psychoactive Drugs (2019)
Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Nichols, C. D., Nichols, D. E., Johnson, M. W. · Clinical Pharmacology and Therapeutics (2016)
Richards, W. A. · Journal of Humanistic Psychology (2016)
Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)
Cited By (2)
Papers in Blossom that reference this study
Aday, J. S., Horton, D. M., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)
Greń, J., Tylš, F., Lasocik, M. et al. · Frontiers in Psychology (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.